Literature DB >> 242199

Possible involvement of GABA in the central actions of benzodiazepines.

W Haefely, A Kulcsár, H Möhler, L Pieri, P Polc, R Schaffner.   

Abstract

The effects of several benzodiazepines on a variety of nervous activities known or presumed to depend on GABA are presented and compared with those of agents that deplete or increase the level of endogenous GABA: antagonism of various convulsant agents in mice, enhancement of presynaptic inhibition in the spinal cord and the cuneate nucleus of cats, decrease of the spontaneous firing rate of cerebellar Purkinje cells in cats and rats, antagonism of bicuculine-induced depression of the strio-nigral-evoked potential in the cat, potentiation of haloperidol-induced catalepsy in rats, GABA-mimetic actions on drug-induced PGO-waves in cats and on eserine-induced circling in guinea pigs. Diazepam slightly increased the GABA level in the cat spinal cord and in the total brain of mice and rats; this increase does not seem to be due to an increase of GABA synthesis. It is concluded that benzodiazepines probably enhance presynaptic inhibition at all levels of the neuraxis and that this effect requires not only the presence of GABA but is also dependent on an activity of GABA-ergic neurons. Benzodiazepines also appear to enhance postsynaptic inhibition where this is mediated by GABA. Many actions of benzodiazepines can be tentatively explained by a stimulus-bound enhancement of GABA effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 242199

Source DB:  PubMed          Journal:  Adv Biochem Psychopharmacol        ISSN: 0065-2229


  68 in total

Review 1.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

2.  Lack of involvement of dopaminergic and GABA neurones in the inhbitory effect of harmaline on the activity of striatal cholinergic neurones in the rat.

Authors:  F Javoy; C Euvrard; A Herbet; J Bockaert; A Enjalbert; Y Agid; J Glowinski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-04       Impact factor: 3.000

3.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

4.  Reversal of the action of amino acid antagonists by barbiturates and other hypnotic drugs.

Authors:  N G Bowery; A Dray
Journal:  Br J Pharmacol       Date:  1978-05       Impact factor: 8.739

5.  Rotational behaviour and cGMP responses following manipulation of nigral mechanisms with chlordiazepoxide. Evidence for enhancement of GABA transmission by benzodiazepines.

Authors:  J L Waddington; A Longden
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

Review 6.  GABAA receptor: Positive and negative allosteric modulators.

Authors:  Richard W Olsen
Journal:  Neuropharmacology       Date:  2018-01-31       Impact factor: 5.250

7.  Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action diazepam.

Authors:  C C Mao; A Guidotti; E Costa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

8.  GABAA Receptors of Cerebellar Granule Cells in Culture: Interaction with Benzodiazepines.

Authors:  Aroldo Cupello; Mario Di Braccio; Elena Gatta; Giancarlo Grossi; Periklis Nikas; Francesca Pellistri; Mauro Robello
Journal:  Neurochem Res       Date:  2013-10-12       Impact factor: 3.996

9.  gamma-Aminobutyric acid and benzodiazepine receptors: copurification and characterization.

Authors:  M Gavish; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

10.  The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine.

Authors:  H M Meinck; K Ricker; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.